Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALPN-101 · 2 trials · 2 indications
The SRI-4 is a composite index of SLE disease improvement that consists of scores derived from the SLE Disease Activity Index 2000 (SLEDAI-2K), the British Isles Lupus Assessment Group (BILAG) 2004 Index, and the Physician's Global Assessment (PGA). Participants classified as responder if they met all of the following criteria: 1) ≥ 4-point reduction in the SLEDAI-2K total score; 2) no new severe disease activity (BILAG A organ score) or more than 1 new moderate organ score (BILAG B) compared with baseline; and 3) No worsening from baseline in participants' lupus disease activity (i.e., increase of ≥0.3 0 on a 3-point scale) in PGA. The SLEDAI-2K total score falls between 0 and 105, with higher scores representing increased disease activity. SLEDAI-2K: assesses improvement in disease activity (range: 0 to 105; higher score = higher severity). BILAG: assesses disease extent, severity (range: A\[severe\] to E\[no disease\]). PGA: assesses worsening in participant's general health.
The BICLA is a responder index developed to measure response to therapy, and it includes scores from the BILAG, SLEDAI-2K, and Physician's Global Assessment (PGA). BICLA response is defined as: 1) at least 1 gradation of improvement in baseline BILAG 2004 scores in all body systems with moderate disease activity at entry (eg, all B \[mild disease\] scores falling to C \[Stable and mild\], or D \[no activity\]); 2) no new BILAG A or more than 1 new BILAG B scores; 3) no worsening of total SLEDAI-2K score from baseline; 4) ≤ 10% deterioration in PGA score. The PGA is measured on a 0 to 100 mm scale with score 0 indicates No Disease Activity and score 100 indicates the most Severe Disease Activity.
The rate of adverse events will be compared between the 2 treatment groups.
| Arm | Type | Description |
|---|---|---|
| ALPN-101 (Acazicolcept) | EXPERIMENTAL | Participants received a weight-based dose of 3 milligrams/kilogram (mg/kg) ALPN-101 once every 2 weeks (Q2W) up to 24 weeks. |
| Placebo | PLACEBO_COMPARATOR | Participants received placebo matched to ALPN-101 up to 24 weeks. |
| Single Ascending Dose ALPN-101 | ACTIVE_COMPARATOR | - |
| Single Dose Placebo | PLACEBO_COMPARATOR | - |
| Multiple Ascending Dose ALPN-101 | ACTIVE_COMPARATOR | - |
| Multiple Dose Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ALPN-101 | DRUG | Intravenous infusion via an infusion pump. |
| Placebo | DRUG | Intravenous infusion via an infusion pump. |
Key Inclusion Criteria Summary * SLE onset ≥ 6 months prior to Screening * Positive ANA and/or elevated anti-dsDNA and/or elevated anti-Smith antibody test * Active lupus at Screening and Baseline, as defined per-protocol and confirmed by the study's medical monitor, including a SLEDAI score at Scr...
Top 20 of 32 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Biogen Inc. | BIIB | 5 | PHASE3 | Litifilimab |
| Bristol-Myers Squibb Company | BMY | 7 | PHASE3 | Deucravacitinib |
| Viatris, Inc. | VTRS | 5 | PHASE3 | Cenerimod |
| Novartis AG Sponsored ADR | NVS | 7 | PHASE3 | Ianalumab |
| AstraZeneca PLC | AZN | 21 | PHASE3 | Medi-546 |
| Johnson & Johnson | JNJ | 1 | PHASE3 | Nipocalimab |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Upadacitinib |
| GSK plc Sponsored ADR | GSK | 3 | PHASE2 | Belimumab |
| Sanofi SA Sponsored ADR | SNY | 2 | PHASE2 | SAR441344 |
| Zenas BioPharma, Inc. | ZBIO | 1 | PHASE2 | Obexelimab |
| Alumis Inc. | ALMS | 1 | PHASE2 | Envudeucitinib |
| Immunovant Inc | IMVT | 1 | PHASE2 | IMVT-1402 |
| Amgen Inc. | AMGN | 1 | PHASE2 | Inebilizumab, Blinatumomab |
| Fate Therapeutics, Inc. | FATE | 2 | PHASE2 | FT819 |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY4298445 |
| Cartesian Therapeutics, Inc. | RNAC | 2 | PHASE2 | Descartes-08 |
| Merck & Co., Inc. | MRK | 1 | PHASE1 | MK-1045 |
| Gilead Sciences, Inc. | GILD | 1 | PHASE1 | KITE-363, Fludarabine, Cyclophosphamide |
| Artiva Biotherapeutics, Inc. | ARTV | 2 | PHASE1 | AB-101, Cyclophosphamide, Fludarabine, Rituximab, Obinutuzumab |
| Cullinan Therapeutics, Inc. | CGEM | 1 | PHASE1 | CLN-978 |
ALPN-101, also known as acazicolcept, is an investigational small molecule being developed by Vertex Pharmaceuticals Incorporated (VRTX). It has been studied in healthy volunteers and in patients with systemic lupus erythematosus (SLE). The drug is currently in clinical development and is not approved by the FDA.
ALPN-101 (acazicolcept) is being studied for the treatment of systemic lupus erythematosus (SLE). A Phase 2 clinical trial evaluated its safety and efficacy in adult patients with SLE across multiple countries, including the United States, France, Hungary, Poland, Puerto Rico, Spain, and Taiwan.
ALPN-101 is being developed by Vertex Pharmaceuticals Incorporated, a biopharmaceutical company traded on the NASDAQ under the ticker symbol VRTX. The drug is also known by the name acazicolcept.
ALPN-101 has completed a Phase 1 trial in healthy volunteers and a Phase 2 trial in patients with systemic lupus erythematosus. Both trials are listed as completed, and the drug remains investigational, meaning it has not received FDA approval.
ALPN-101 has been studied in two completed clinical trials. NCT03748836 was a Phase 1 study in 96 healthy volunteers in Australia, and NCT04835441 was a Phase 2 study in 76 patients with systemic lupus erythematosus across multiple countries.
Yes, ALPN-101 is also known as acazicolcept. The Phase 2 trial in systemic lupus erythematosus used the name acazicolcept in its title, confirming that both names refer to the same investigational drug.